Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
- Funding
- Est. $4M total
- Deadline
- February 11, 2027
- Who can apply
- State governments, County governments, City or township governments +11 more
Description
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled colleges and universities
- Federally recognized Native American tribal governments
- Public and Indian housing authorities
- Other Native American tribal organizations
- Nonprofits with 501(c)(3) status
- Nonprofits without 501(c)(3) status
- Private colleges and universities
- For-profit organizations (other than small businesses)
- Small businesses
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibilityForeign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Industry Tags
About This Grant
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Funding Information
- Estimated Total Program Funding
- $4,000,000
Eligibility Overview
Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.
Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.
How to Apply
- 1
Review the full opportunity
Read the complete Notice of Funding Opportunity (NOFO) for this National Institutes of Health program on its official page (https://www.grants.gov/search-results-detail/361832).
- 2
Confirm eligibility
Check that your organization meets every requirement set by National Institutes of Health — applicant type, location, registration status, and any prior-award restrictions.
- 3
Prepare required documents
Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.
- 4
Submit before the deadline
This opportunity closes on February 11, 2027. Submit well before the deadline to leave time for fixes.
Grant Writing Tips
General tips for preparing your application:
- ✓Start early: registration and review steps take time.
- ✓Match your needs statement to the funder's stated priorities.
- ✓Have someone outside your team check the budget narrative.
More Grants from National Institutes of Health
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) →
- NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) →
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) →
- View all 356 grants from NIH →
Frequently Asked Questions
Who is eligible for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)?
Eligible applicants include: State governments, County governments, City or township governments +11 more. Always confirm on the official listing.
How much funding does Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) provide?
The total estimated program funding for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) is $4,000,000.
When is the deadline for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)?
The application deadline for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) is February 11, 2027. Submit well before the deadline to leave time for fixes.
How do I apply for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)?
Apply for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) through the official grant page (https://www.grants.gov/search-results-detail/361832). Confirm your eligibility and prepare your application materials before the deadline.
Helpful Resources
Need help writing your grant application?
Try Instrumentl — Grant Writing Software →Starting a nonprofit to apply for grants?
Launch your nonprofit with Swyft Filings →GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.